Eagle Pharmaceuticals, Inc. Assets, Fair Value Disclosure
Eagle Pharmaceuticals, Inc. had Assets, Fair Value Disclosure of $40.85 million as of 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis › Fair Value, Net Asset (Liability)
us-gaap:AssetsFairValueDisclosure · last filed 2022-05-09
- 2022-03-31: Assets, Fair Value Disclosure $40.85M.
- 2021-12-31: Assets, Fair Value Disclosure $68.37M.
- 2021-09-30: Assets, Fair Value Disclosure $109.88M.
- 2021-06-30: Assets, Fair Value Disclosure $121.45M.
| Period end | Assets, Fair Value Disclosure | Assets, Fair Value Disclosure as first filed |
|---|---|---|
| 2022-03-31 | $40.85M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $68.37M 10-Q · filed 2022-05-09 | |
| 2021-09-30 | $109.88M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $121.45M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $124.50M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $91.88M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $98.69M 10-Q · filed 2020-11-02 | |
| 2019-12-31 | $85.63M 10-K · filed 2021-03-05 | $105.67M 10-Q · filed 2020-11-02 |